CNTA - Company ID 0001847903
The table below shows Centessa Pharmaceuticals plc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$72.22M | -$57.25M | -$37.29M | -$47.84M | -$50.02M | -$11.63M |
| Capital expenditure | - | - | $0.00 | $88.00K | $240.00K | $37.00K |
| Investing cash flow | $42.71M | -$222.39M | $16.76M | -$86.34M | -$240.00K | $63.52M |
| Dividends paid | - | - | - |
Centessa Pharmaceuticals plc reported operating cash flow of -$193.82M for fiscal year 2025. That is down 36.4% from -$142.06M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$5.83M (FY 2019) to -$193.82M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $30.47M | $3.09M | $10.49M | $0.00 | $74.00K | $241.89M |